PL2264170T3 - Markery dla komórek przedrakowych i rakowych oraz sposób zakłócania proliferacji tych komórek - Google Patents

Markery dla komórek przedrakowych i rakowych oraz sposób zakłócania proliferacji tych komórek

Info

Publication number
PL2264170T3
PL2264170T3 PL10171933T PL10171933T PL2264170T3 PL 2264170 T3 PL2264170 T3 PL 2264170T3 PL 10171933 T PL10171933 T PL 10171933T PL 10171933 T PL10171933 T PL 10171933T PL 2264170 T3 PL2264170 T3 PL 2264170T3
Authority
PL
Poland
Prior art keywords
cancer
markers
interfere
cell proliferation
oligonucleotides
Prior art date
Application number
PL10171933T
Other languages
English (en)
Inventor
Luis O. Burzio
Jaime E. Villegas
Veronica A. Burzio
Original Assignee
Andes Biotechnologies S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551438&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2264170(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Andes Biotechnologies S.A. filed Critical Andes Biotechnologies S.A.
Publication of PL2264170T3 publication Critical patent/PL2264170T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL10171933T 2003-05-21 2004-05-21 Markery dla komórek przedrakowych i rakowych oraz sposób zakłócania proliferacji tych komórek PL2264170T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47210603P 2003-05-21 2003-05-21

Publications (1)

Publication Number Publication Date
PL2264170T3 true PL2264170T3 (pl) 2017-08-31

Family

ID=33551438

Family Applications (3)

Application Number Title Priority Date Filing Date
PL10171926T PL2270159T3 (pl) 2003-05-21 2004-05-21 Markery dla komórek przedrakowych i rakowych oraz sposób zakłócania proliferacji tych komórek
PL04752867T PL1625142T3 (pl) 2003-05-21 2004-05-21 Markery komórek przedrakowych i rakowych oraz sposób zaburzania proliferacji tych komórek
PL10171933T PL2264170T3 (pl) 2003-05-21 2004-05-21 Markery dla komórek przedrakowych i rakowych oraz sposób zakłócania proliferacji tych komórek

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL10171926T PL2270159T3 (pl) 2003-05-21 2004-05-21 Markery dla komórek przedrakowych i rakowych oraz sposób zakłócania proliferacji tych komórek
PL04752867T PL1625142T3 (pl) 2003-05-21 2004-05-21 Markery komórek przedrakowych i rakowych oraz sposób zaburzania proliferacji tych komórek

Country Status (13)

Country Link
US (6) US8318686B2 (pl)
EP (3) EP2270159B1 (pl)
JP (3) JP5201834B2 (pl)
AT (1) ATE506437T1 (pl)
BR (1) BRPI0410789B8 (pl)
CA (1) CA2526639C (pl)
DE (1) DE602004032329D1 (pl)
DK (3) DK2264170T3 (pl)
ES (3) ES2365511T3 (pl)
HU (1) HUE032575T2 (pl)
MX (1) MXPA05012620A (pl)
PL (3) PL2270159T3 (pl)
WO (1) WO2005001030A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5201834B2 (ja) 2003-05-21 2013-06-05 アンデス バイオテクノロジーズ ソシエダード アノニマ 前癌と癌細胞用のマーカー、及び前記細胞の増殖阻害方法
CA2585587C (en) * 2004-10-29 2016-02-16 Maarten Tjerk Penning Methods using mitochondrial nucleic acid for determining a health status of an individual
CN102589945B (zh) * 2012-02-16 2013-10-23 中国人民解放军第三军医大学第二附属医院 骨髓涂片存放盒
CN105283466A (zh) * 2013-03-14 2016-01-27 安第斯生物技术股份有限公司 用于检测和治疗多发性骨髓瘤的方法
WO2014153209A1 (en) * 2013-03-14 2014-09-25 Andes Biotechnologies S.A. Antisense oligonucletotides for treatment of cancer stem cells
WO2015066485A2 (en) * 2013-10-31 2015-05-07 The Children's Hospital Of Philadelphia Mitochondrial disease genetic diagnostics
CA2939860A1 (en) * 2014-03-14 2015-10-08 Andes Biotechnologies S.A. Pharmaceutical compositions comprising rna and use for treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5646262A (en) 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US6316210B1 (en) 1995-12-20 2001-11-13 Subsidiary No. 3, Inc. Genetic suppressor elements against human immunodeficiency virus
US6426412B1 (en) 1995-12-20 2002-07-30 Subsidiary No. 3, Inc. Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6720413B1 (en) 1997-03-04 2004-04-13 Musc Foundation For Research Development Methods and compositions for diagnosis and treatment of cancer
US6333152B1 (en) 1997-05-21 2001-12-25 The Johnshopkins University Gene expression profiles in normal and cancer cells
US6071743A (en) 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6537972B1 (en) 1997-06-02 2003-03-25 Subsidiary No. 3., Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6764822B1 (en) * 1997-09-19 2004-07-20 Sequenom, Inc. DNA typing by mass spectrometry with polymorphic DNA repeat markers
JP3251219B2 (ja) 1997-10-13 2002-01-28 雅嗣 田中 ヒトミトコンドリアｄｎａを用いた遺伝子検出方法
US6417169B1 (en) 1998-04-23 2002-07-09 Genesense Technologies Inc. Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
US20030092063A1 (en) * 1998-05-15 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999065928A2 (en) 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
US6280946B2 (en) 1998-08-07 2001-08-28 Boston Probes, Inc. PNA probes, probe sets, methods and kits pertaining to the universal detection of bacteria and eucarya
WO2000026363A1 (en) * 1998-11-04 2000-05-11 Genset GENOMIC AND COMPLETE cDNA SEQUENCES OF HUMAN ADIPOCYTE-SPECIFIC APM1 AND BIALLELIC MARKERS THEREOF
US6576759B2 (en) 1999-02-10 2003-06-10 Pangene Corporation Antisense inhibition of RAD51
EP1208225A2 (en) 1999-04-20 2002-05-29 Mitokor Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease
WO2001016323A2 (en) * 1999-09-01 2001-03-08 Subsidiary N0.3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6573050B1 (en) 1999-10-29 2003-06-03 Sunnybrook & Women's College Health Sciences Centre Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma
WO2001076532A2 (en) 2000-04-11 2001-10-18 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US6673917B1 (en) 2000-09-28 2004-01-06 University Of Ottawa Antisense IAP nucleic acids and uses thereof
US20040253728A1 (en) * 2000-11-10 2004-12-16 Claes Gustafsson New method
AU2002219707A1 (en) * 2000-12-04 2002-06-18 Primagen B.V. Testing endosymbiont cellular organelles and compounds identifiable therewith
US6573051B2 (en) * 2001-03-09 2003-06-03 Molecular Staging, Inc. Open circle probes with intramolecular stem structures
US6544958B2 (en) 2001-03-26 2003-04-08 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Therapy of respiratory influenza virus infection using free and liposome-encapsulated ribonucleotides
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
EP1432823A4 (en) * 2001-08-30 2005-03-02 Univ Emory MITOCHONDRIAL BIOLOGICAL EXPRESSION ARRAYS
JP5201834B2 (ja) 2003-05-21 2013-06-05 アンデス バイオテクノロジーズ ソシエダード アノニマ 前癌と癌細胞用のマーカー、及び前記細胞の増殖阻害方法
US7374927B2 (en) * 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples

Also Published As

Publication number Publication date
JP5775057B2 (ja) 2015-09-09
CA2526639C (en) 2018-03-20
BRPI0410789B8 (pt) 2021-05-25
US9359648B2 (en) 2016-06-07
EP2270159A1 (en) 2011-01-05
EP1625142B1 (en) 2011-04-20
DK2270159T3 (en) 2015-04-20
US8895719B2 (en) 2014-11-25
ATE506437T1 (de) 2011-05-15
US20060241033A1 (en) 2006-10-26
US20150064700A1 (en) 2015-03-05
JP5201834B2 (ja) 2013-06-05
US8318686B2 (en) 2012-11-27
WO2005001030A2 (en) 2005-01-06
EP2264170A1 (en) 2010-12-22
US20130149371A1 (en) 2013-06-13
WO2005001030A3 (en) 2005-12-22
ES2536002T3 (es) 2015-05-19
JP2015096069A (ja) 2015-05-21
EP1625142A4 (en) 2007-04-04
US20160304971A1 (en) 2016-10-20
ES2365511T3 (es) 2011-10-06
PL1625142T3 (pl) 2011-11-30
ES2618210T3 (es) 2017-06-21
US20210348236A1 (en) 2021-11-11
US9903000B2 (en) 2018-02-27
CA2526639A1 (en) 2005-01-06
HUE032575T2 (en) 2017-10-30
US10876166B2 (en) 2020-12-29
BRPI0410789A (pt) 2006-08-01
EP2264170B1 (en) 2017-02-08
EP1625142A2 (en) 2006-02-15
JP2007519395A (ja) 2007-07-19
US20180340232A1 (en) 2018-11-29
BRPI0410789B1 (pt) 2020-11-10
DK2264170T3 (en) 2017-03-20
JP2013066478A (ja) 2013-04-18
MXPA05012620A (es) 2006-05-25
PL2270159T3 (pl) 2015-08-31
DK1625142T3 (da) 2011-08-08
DE602004032329D1 (de) 2011-06-01
EP2270159B1 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
BRPI0517613A (pt) oligonucleotìdeos lna e tratamento de cáncer
WO2006047842A3 (en) Modified nucleosides for rna interference
EP0763052A4 (en) ANTISENSE OLIGONUCLEOTIDE MODULATION OF THE Raf GENE EXPRESSION
WO2005078139A3 (en) DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
TW200519202A (en) Modulation of eIF4E expression
NZ587060A (en) Rna interference for the treatment of heart failure
WO2010017436A3 (en) Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides
EA201171131A1 (ru) Усовершенствованное определение экспрессии генов
WO2005049630A3 (en) Antisense modulation of kinesin-like 1 expression
PH12013501723A1 (en) Phosphoramidate derivatives of 5 - fluoro - 2 1 - deoxyuridine for use in the treatment of cancer
WO2005059172A3 (en) Method and nucleic acids for the improved treatment of breast cell proliferative disorders
WO2004071407A3 (en) Antisense modulation of ptp1b expression
MX2009002462A (es) Siarn y metodos de manufactura del mismo.
PL1673473T3 (pl) Zastosowanie polimorfizmów genetycznych związanych ze skutecznością leczenia chorób zapalnych
PL2270159T3 (pl) Markery dla komórek przedrakowych i rakowych oraz sposób zakłócania proliferacji tych komórek
WO2008087558A3 (en) Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use
WO2008051523A3 (en) Carbazole derivatives useful as medicaments in cancer therapy
WO2005047536A3 (en) Detection of genomic amplification and deletion in cancer
WO2005000320A3 (en) Use of double-stranded ribonucleic acid for inducing cell lysis
WO2011133584A3 (en) Nucleic acid compounds for inhibiting hras gene expression and uses thereof
PL372370A1 (pl) Drobnoustroje jako nośnik sekwencji nukleotydów kodujących antygeny komórkowe do leczenia nowotworów
WO2004104199A3 (en) Modulation of gene expression using dna-dna hybrids
WO2011139842A3 (en) Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
WO2005001031A3 (en) Modulation of the rna interference pathway
WO2009115927A3 (en) Nucleotide analogues with quaternary carbon stereogenic centers and methods of use